Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bi-monthly capecitabine + oxaliplatin + bevacizumab for advanced colorectal cancer
ISRCTN41540878Phase 4Completed
- Sponsor
- Cancer Trials New Zealand
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capecitabine, oxaliplatin and bevacizumab in colorectal cancer (CRC), sponsored by Cancer Trials New Zealand. Primary endpoint: Progression-free survival. Started May 2006; status: completed.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN41540878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN41540878.